HRT Financial’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

HRT Financial’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-203,229	Closed	-$258K	–	3372
2023 Q3	$258K	Buy	+203,229	New	+$177K	﹤0.01%	1730
2023 Q2	–	Sell	-19,760	Closed	-$8K	–	3570
2023 Q1	$8K	Buy	+19,760	New	+$10.4K	﹤0.01%	2271
2022 Q4	–	Sell	-32,642	Closed	-$23K	–	3463
2022 Q3	$23K	Buy	+32,642	New	+$37K	﹤0.01%	2481
2022 Q2	–	Sell	-13,933	Closed	-$28K	–	3973
2022 Q1	$28K	Buy	+13,933	New	+$33.1K	﹤0.01%	2795
2021 Q3	–	Sell	-37,239	Closed	-$196K	–	3913
2021 Q2	$196K	Sell	37,239 -26,476	-42%	-$127K	﹤0.01%	2400
2021 Q1	$296K	Buy	+63,715	New	+$289K	﹤0.01%	2101

HRT Financial's ZYNE Position: Q4 2023 in Review

HRT Financial sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 203,229 shares — an estimated $258K sold.

HRT Financial first reported a position in ZYNE in Q1 2021 and held it in 6 quarters. The position peaked at $296K in Q1 2021. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.

HRT Financial reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
HRT Financial sold 203,229 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $258K.
HRT Financial first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2021 and held it in 6 quarters.
HRT Financial's Zynerba Pharmaceuticals, Inc position peaked at $296K in Q1 2021.
0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.

Based on HRT Financial's 13F filing for Q4 2023, filed 9 Feb 2024.